← All Rafael Holdings, INC filings

Rafael Holdings, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
RFL
Rafael Holdings, INC
10-K: Rafael Holdings Reports FY25 Results, Cyclo Merger Impact
Rafael Holdings reported a reduced net loss for fiscal year 2025, driven by the Cyclo merger and R&D efforts, while advancing its lead drug candidate Trappsol Cyclo for NPC1.
NYSE
RFL
Rafael Holdings, INC
10-K/A: Rafael Holdings Files Amendment to Annual Report, Revises Risk Factor and Includes New Officer Certifications
Rafael Holdings has filed an amendment to its annual report to revise a risk factor and include new certifications from its Principal Executive Officer and Principal Financial Officer.
NYSE
RFL
Rafael Holdings, INC
10-K/A: Rafael Holdings Amends Annual Report, Details Strategic Shift and Merger Plans
Rafael Holdings files an amended annual report, outlining a strategic shift towards therapeutics and detailing a planned merger with Cyclo Therapeutics.
NYSE
RFL
Rafael Holdings, INC
10-K: Rafael Holdings Reports Annual Results, Highlights Strategic Shift Towards Clinical Programs
Rafael Holdings' annual report details a strategic shift towards clinical-stage pharmaceutical investments, particularly focusing on the planned merger with Cyclo Therapeutics and its lead drug, Trappsol Cyclo.